Charts
23 Apr, 2024
22 Apr, 2024
21 Apr, 2024
20 Apr, 2024
19 Apr, 2024
18 Apr, 2024
17 Apr, 2024
16 Apr, 2024
15 Apr, 2024
12 Apr, 2024
11:48
Seeking Alpha
11 Apr, 2024
News
13 Apr, 2024
12:08
Yahoo! Finance
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...
29 Mar, 2024
Gainers
Qilian Intl Hldg Gr (NASDAQ:QLI) shares rose 63.8% to $1.04 during Friday's after-market session. The market value of their ...
19 Mar, 2024
12:00
Yahoo! Finance
BRIDGEWATER, N.J., March 19, 2024 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”), a clinical-stage biopharmaceutical company focused on developing proprietary, innovative, and differentiated therapies for the treatment of immuno-inflammatory conditions, today announced that David Domzalski, President and Chief Executive Officer, and Dr. Iain Stuart, Chief Scientific Officer, will participate in a fireside chat at the H.C. Wainwright 2nd Annual Autoimmune & In
03 Mar, 2024
12:03
Yahoo! Finance
VYNE Therapeutics ( NASDAQ:VYNE ) Full Year 2023 Results Key Financial Results Net loss: US$27.9m (loss narrowed by 18...
01 Mar, 2024
29 Feb, 2024
VYNE Therapeutics (NASDAQ:VYNE) reported its Q4 earnings results on Thursday, February 29, 2024 at 08:00 AM.
Here's what investors need ...
13:00
Yahoo! Finance
2023 was a transformative year for VYNE, marked by the achievement of clinical proof-of-concept for VYN201 in vitiligo and a successful financing with a syndicate of leading institutional investorsAnticipate commencing a Phase 2b trial for VYN201 and a Phase 1a trial for VYN202 in Q2 2024Ended 2023 with $93.3 million of cash, cash equivalents, restricted cash and marketable securities, providing runway through the end of 2025 and multiple expected clinical milestones BRIDGEWATER, N.J., Feb. 29,
27 Feb, 2024
13:00
Yahoo! Finance
Oral presentation on March 7, 2024 will review positive safety and efficacy data for novel BET inhibitor VYN201 BRIDGEWATER, N.J., Feb. 27, 2024 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”), a clinical-stage biopharmaceutical company developing proprietary, innovative and differentiated therapies for the treatment of immuno-inflammatory conditions, today announced that Dr. Iain Stuart, Chief Scientific Officer of the Company, will deliver an oral presentati
21 Feb, 2024
13:00
Yahoo! Finance
BRIDGEWATER, N.J., Feb. 21, 2024 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”), a clinical-stage biopharmaceutical company developing proprietary, innovative, and differentiated therapies for the treatment of immuno-inflammatory conditions, today announced that David Domzalski, President and Chief Executive Officer, will participate in a fireside chat at the TD Cowen 44th Annual Health Care Conference at the Boston Marriott Copley Place in Boston, Massachuse
02 Feb, 2024
Generally, when a single insider buys stock, it is usually not a big deal. However, when several insiders are buying...
16 Jan, 2024
The most oversold stocks in the health care presents an opportunity to buy into undervalued companies.
The RSI is a momentum ...
11 Jan, 2024
12:51
FinancialContent
Shares of Richardson Electronics, Ltd. (NASDAQ: RELL) fell sharply in today’s pre-market trading after the company posted ...
12:37
FinancialContent
InvestorPlace - Stock Market News, Stock Advice & Trading Tips
It's time to dive into the biggest pre-market stock movers for Thursday as we check out all of the hottest news this morning!
The post Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday appeared first on InvestorPlace.
More From InvestorPlace
The #1 AI Investment Might Be This Company You’ve Never Heard Of
Musk’s “Project Omega” May Be Set to Mint New Millionaires. Here’s How to Get In.
The Rich Use This Income Secret (NOT Dividends) Far More Than Regular Investors
10 Jan, 2024
13:00
Yahoo! Finance
VYN201 demonstrated positive effect on key biomarkers relevant to vitiligo Data supports VYN201’s rapid onset of action and previously announced positive clinical resultsProgram is on track for Phase 2b initiation in Q2 BRIDGEWATER, N.J., Jan. 10, 2024 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”), a clinical-stage biopharmaceutical company developing proprietary, innovative and differentiated therapies for the treatment of immuno-inflammatory conditions, to
03 Jan, 2024
13:00
Yahoo! Finance
BRIDGEWATER, N.J., Jan. 03, 2024 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”), a clinical-stage biopharmaceutical company developing proprietary, innovative and differentiated therapies for the treatment of immuno-inflammatory conditions, today announced the appointment of Christine Borowski, Ph.D., to its board of directors, effective as of January 1, 2024. “We are pleased to welcome Dr. Borowski to our Board of Directors during this important time in the
20 Nov, 2023
13 Nov, 2023
VYNE Therapeutics (NASDAQ:VYNE) reported its Q3 earnings results on Monday, November 13, 2023 at 07:45 AM.
Here's what investors need to ...
12:45
Yahoo! Finance
Transformative capital raise of $88.2 million from leading healthcare investors provides funding for BET inhibitor programs through the end of 2025 Phase 2b preparatory activities progressing for VYN201 in nonsegmental vitiligo following positive Phase 1b results On track for VYN202 IND submission by year-end 2023, with plans to begin Phase 1a trial in Q1 2024 BRIDGEWATER, N.J., Nov. 13, 2023 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”), a clinical-stage bi
07 Nov, 2023
Event will highlight VYN201 Phase 1b trial results, VYN202 preclinical data and VYNE’s clinical development plans Program to feature KOL presentation covering unmet need and current treatment landscape in vitiligo BRIDGEWATER, N.J., Nov. 07, 2023 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”), a clinical-stage biopharmaceutical company developing proprietary, innovative and differentiated therapies for the treatment of immuno-inflammatory conditions, today an
01 Nov, 2023
20:15
Yahoo! Finance
Transformative capital raise to fund VYNE’s BET inhibitor programs through the end of 2025BRIDGEWATER, N.J., Nov. 01, 2023 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”), a clinical-stage biopharmaceutical company developing proprietary, innovative and differentiated therapies for the treatment of immuno-inflammatory conditions, today announced the closing of its previously announced private placement financing (the “PIPE”). In the PIPE, VYNE received aggrega
30 Oct, 2023
19:06
FinancialContent
U.S. stocks traded higher toward the end of trading, with the Dow Jones index gaining more than 500 points on Monday.
The Dow traded ...
17:55
FinancialContent
Gainers
Miromatrix Medical Inc. (NASDAQ: MIRO) shares climbed 230.7% to $3.3401 after United Therapeutics agreed to acquire the ...
Gainers
Miromatrix Medical (NASDAQ:MIRO) shares increased by 217.2% to $3.3 during Monday's regular session. The current volume of 2.9 ...
17:29
FinancialContent
Earlier today,VYNE Therapeutics Inc(NASDAQ: VYNE) released new preclinical data showing the positive effect of its VYN202 in ...
U.S. stocks traded higher midway through trading, with the Nasdaq Composite gaining more than 100 points on Monday.
The Dow traded up ...
VyneTherapeutics Inc. (NASDAQ: VYNE) shares are trading higher Monday after the company announced a private placement of $88 ...
U.S. stocks traded higher this morning, with the Dow Jones index gaining more than 250 points on Monday.
Following the market opening ...
Gainers
Miromatrix Medical (NASDAQ:MIRO) stock rose 223.1% to $3.36 during Monday's pre-market session. The company's market cap stands ...
11:20
Yahoo! Finance
Treatment with VYN202 resulted in significant inhibition of key inflammatory biomarkers and substantial resolution of the signs and symptoms of psoriasis and rheumatoid arthritisFollowing completion of recent financing, VYNE expects to initiate a Phase 1a SAD/MAD clinical trial in Q1 2024, followed by Phase 1b trials in moderate-to-severe plaque psoriasis and in moderate-to-severe adult-onset rheumatoid arthritis in the second half of 2024Preclinical data and clinical programs to be discussed at
Transaction provides $88 million to fund VYNE’s clinical development programs for VYN201 and VYN202 through the end of 2025BRIDGEWATER, N.J., Oct. 30, 2023 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”), a clinical-stage biopharmaceutical company developing proprietary, innovative and differentiated therapies for the treatment of immuno-inflammatory conditions, today announced that the Company has signed a securities purchase agreement with certain healthcare
11:00
Yahoo! Finance
Clinical proof-of-concept achieved with statistically significant dose dependent reduction in F-VASI score from baseline for the VYN201 1.0% and 2.0% cohorts compared to the 0.5% cohort VYN201 was generally well-tolerated with no clinically relevant treatment emergent adverse events across all dose cohorts Clinical response and rapid onset of action suggest VYN201 has the potential to be the category leader in the treatment of nonsegmental vitiligo VYN201 is expected to advance into a Phase 2b c
18 Oct, 2023
Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. For the Vanguard Extended Market ETF (VXF), we found that the implied analyst target price for the ETF based upon its underlying holdings is $174.78 per unit.
26 Sep, 2023
Gainers
Galecto (NASDAQ:GLTO) stock increased by 40.3% to $0.81 during Tuesday's after-market session. At the close, Galecto's trading ...
06 Sep, 2023
12:00
Yahoo! Finance
BRIDGEWATER, N.J., Sept. 06, 2023 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”), a clinical-stage biopharmaceutical company focused on developing proprietary, innovative, and differentiated therapies for the treatment of immuno-inflammatory conditions, today announced that David Domzalski, President and Chief Executive Officer, will participate in the H.C. Wainwright 25th Annual Global Investment Conference being held September 11-13, 2023. Management will a
14 Aug, 2023
12:00
Yahoo! Finance
Anticipate announcing preliminary Phase 1b safety and efficacy data for pan-BD BET inhibitor, VYN201, in nonsegmental vitiligo in Q3 2023 IND-enabling studies for VYN202, a potential best-in-class oral small molecule BD2-selective BET inhibitor, are ongoing in anticipation of indication selection in Q4 2023 and initiating a Phase 1 trial in Q1 2024 BRIDGEWATER, N.J., Aug. 14, 2023 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”), a clinical-stage biopharmaceuti
18 May, 2023
BRIDGEWATER, N.J., May 18, 2023 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”), a clinical-stage biopharmaceutical company focused on developing proprietary, innovative and differentiated therapies for the treatment of immuno-inflammatory conditions, today announced that members of management will attend the Biotechnology Innovation Organization (BIO) International Convention, taking place June 5-8, 2023 at the Boston Convention & Exhibition Center in Boston,
12 May, 2023
Gainers
ARS Pharmaceuticals (NASDAQ:SPRY) shares increased by 79.4% to $8.11 during Friday's regular session. ARS Pharmaceuticals's ...
17:09
FinancialContent
Gainers
GSI Technology, Inc. (NASDAQ: GSIT) shares surged 108% to $3.4207. GSI Technology is expected to announce financial ...
11 May, 2023
VYNE Therapeutics (NASDAQ:VYNE) reported its Q1 earnings results on Thursday, May 11, 2023 at 04:00 PM.
Here's what investors need to ...
20:01
Yahoo! Finance
Anticipate topline 16-week data for all three cohorts from the Phase 1b trial for pan-BD BET inhibitor, VYN201, in nonsegmental vitiligo in the third quarter of 2023 IND-enabling studies for VYN202, a potential best-in-class oral small molecule BD2-selective BET inhibitor, are ongoing in anticipation of an IND filing by year-end 2023 BRIDGEWATER, N.J., May 11, 2023 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”), a clinical-stage biopharmaceutical company focu
10 May, 2023
Gainers
CTI BioPharma (NASDAQ:CTIC) shares rose 85.2% to $8.93 during Wednesday's regular session. As of 13:30 EST, CTI BioPharma's ...
01 May, 2023
Preclinical studies suggest VYN202 has the potential to be the most potent and selective BET inhibitor in development VYN202 has demonstrated a potent anti-inflammatory and anti-fibrotic effect in multiple validated preclinical models of autoimmune disease IND-enabling studies are ongoing in anticipation of an IND filing by year-end BRIDGEWATER, N.J., May 01, 2023 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”), a clinical-stage biopharmaceutical company devel
19 Apr, 2023
U.S. stocks traded mixed toward the end of trading, with the Nasdaq Composite turning higher on Wednesday.
The Dow traded down 0.23% ...
17:04
FinancialContent
Gainers
China Jo-Jo Drugstores, Inc. (NASDAQ: CJJD) gained 85.2% to $1.25 after the company announced the termination of its ...
VYNE Therapeutics Inc(NASDAQ: VYNE) announced new preclinical data showing the effect of its novel pan-BET inhibitor, VYN201, ...
U.S. stocks traded lower this morning, with the Dow Jones dropping over 100 points on Wednesday.
Following the market opening ...
Gainers
Virax Biolabs Group (NASDAQ:VRAX) shares rose 34.2% to $0.81 during Wednesday's pre-market session. The market value of their ...
16 Apr, 2023
InvestorPlace - Stock Market News, Stock Advice & Trading Tips
You have to be patient when investing in pharma stocks. But sometimes the risk and the wait aren't worth the rewards.
The post 7 Sorry Pharma Stocks to Sell in April Before It’s Too Late appeared first on InvestorPlace.
More From InvestorPlace
Buy This $5 Stock BEFORE This Apple Project Goes Live
The Best $1 Investment You Can Make Today
It doesn’t matter if you have $500 or $5 million. Do this now.
Massive Bear Market “Divergence Event” Ahead… And The #1 Way to Play It
30 Mar, 2023
17:33
FinancialContent
VYNE Therapeutics Inc(NASDAQ: VYNE) announced first-in-humanpharmacokinetic and hematology datafrom its Phase 1a ...
23 Mar, 2023
12:03
FinancialContent
Gainers
ZyVersa Therapeutics, Inc. (NASDAQ: ZVSA) shares rose 82.8% to $2.98 in pre-market trading. ZyVersa Therapeutics recently ...
11:32
FinancialContent
InvestorPlace - Stock Market News, Stock Advice & Trading Tips
We're starting off the day with a look at the biggest pre-market stock movers traders need to know about on Thursday morning!
The post Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday appeared first on InvestorPlace.
More From InvestorPlace
Buy This $5 Stock BEFORE This Apple Project Goes Live
The Best $1 Investment You Can Make Today
It doesn’t matter if you have $500 or $5 million. Do this now.
Massive Bear Market “Divergence Event” Ahead… And The #1 Way to Play It
09 Mar, 2023
07 Mar, 2023
15 Feb, 2023
10 Feb, 2023
08 Feb, 2023
Gainers
23andMe Holding (NASDAQ:ME) shares moved upwards by 12.3% to $2.83 during Wednesday's after-market session. Trading volume for ...
13 Jan, 2023
Gainers
Jasper Therapeutics (NASDAQ:JSPR) stock rose 32.1% to $2.18 during Friday's pre-market session. The market value of their ...
10 Jan, 2023
U.S. stocks traded higher toward the end of trading, with the Dow Jones gaining more than 100 points on Tuesday.
The Dow traded up ...
19:11
FinancialContent
Gainers
Sotera Health Company (NASDAQ: SHC) shares jumped 92% to $16.59 after the company announced its subsidiaries have reached ...
Gainers
Sotera Health (NASDAQ:SHC) stock moved upwards by 86.9% to $16.15 during Tuesday's regular session. The current volume of 38.4 ...
VYNE Therapeutics Inc(NASDAQ: VYNE) announced that the first vitiligo patienthad been dosedin a Phase 1a/b trial of ...
Gainers
Prenetics Global (NASDAQ:PRE) stock rose 74.7% to $3.25 during Tuesday's pre-market session. The market value of their ...
12:55
FinancialContent
Gainers
VYNE Therapeutics Inc. (NASDAQ: VYNE) rose 82.2% to $0.35 in pre-market trading after the company said first vitiligo ...
12:28
FinancialContent
InvestorPlace - Stock Market News, Stock Advice & Trading Tips
We're starting off the day with an overview of the biggest pre-market stock movers traders need to know about for Tuesday!
The post Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday appeared first on InvestorPlace.
More From InvestorPlace
Buy This $5 Stock BEFORE This Apple Project Goes Live
The Best $1 Investment You Can Make Today
Early Bitcoin Millionaire Reveals His Next Big Crypto Trade “On Air”
It doesn’t matter if you have $500 or $5 million. Do this now.
09 Jan, 2023
Gainers
VYNE Therapeutics (NASDAQ:VYNE) shares rose 87.0% to $0.36 during Monday's after-market session. At the close, VYNE ...
18:42
Why Cutera Shares Are Trading Lower By 23%? Here Are Other Stocks Moving In Monday's Mid-Day Session
FinancialContent
Gainers
CinCor Pharma, Inc. (NASDAQ: CINC) shares jumped 137% to $27.93 after AstraZeneca announced it will acquire the company ...
13:04
FinancialContent
Gainers
CinCor Pharma, Inc. (NASDAQ: CINC) rose 140.2% to $28.30 in pre-market trading after AstraZeneca announced plans to buy ...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips
We're starting off the week with a look at the biggest pre-market stock movers traders need to know about on Monday morning!
The post Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday appeared first on InvestorPlace.
More From InvestorPlace
Buy This $5 Stock BEFORE This Apple Project Goes Live
The Best $1 Investment You Can Make Today
Early Bitcoin Millionaire Reveals His Next Big Crypto Trade “On Air”
It doesn’t matter if you have $500 or $5 million. Do this now.
05 Jan, 2023
18:01
FinancialContent
Gainers
Bellerophon Therapeutics, Inc. (NASDAQ: BLPH) shares surged 179.3% to $2.4585 after the company announced that it has ...
Gainers
Bellerophon Therapeutics (NASDAQ:BLPH) stock rose 171.1% to $2.48 during Thursday's regular session. As of 12:30 EST, this ...
07 Dec, 2022
10 Nov, 2022
22 Sep, 2022
On Thursday, 1076 companies hit new 52-week lows.
Areas of Significance In Today's 52-Week Lows:
The company with ...
12 Aug, 2022
10 Aug, 2022
17 Jun, 2022
12 May, 2022
07 Apr, 2022
17 Mar, 2022
19 Jan, 2022
13 Jan, 2022
13 Dec, 2021
06 Dec, 2021